TGA Lab Finds Counterfeit Retatrutide With No Retatrutide
TGA labs found a vial sold as retatrutide contained undeclared semaglutide at about eight times registered levels, as AHPRA tightens prescriber rules.
Laboratory testing by the Therapeutic Goods Administration (TGA) has found that a vial sold in Australia as the investigational peptide retatrutide contained no retatrutide at all. The product instead contained undeclared semaglutide at a level the regulator described as approximately eight times higher than the level found in semaglutide products assessed by the TGA and included in the Australian Register of Therapeutic Goods.
The testing followed a serious adverse event report. In a safety advisory published on 14 September 2026, the TGA states that the consumer experienced uncontrollable vomiting, resulting in a torn oesophagus, and required hospital treatment. The regulator obtained the sample in its original unmarked vial during its investigation, which is working to locate the source or supply of the product.
An unapproved product with no legitimate supply chain
Retatrutide is currently undergoing clinical trials in humans and has not been approved by the TGA or any comparable international regulator, the advisory states. Any retatrutide product accessed outside of a clinical trial could be a counterfeit product, and the regulator said it should not be used outside a clinical trial setting.
The finding extends a documented pattern rather than opening a new one. In June, Victoria’s Chief Health Officer reported six cases of acute liver toxicity linked to an unapproved product labelled as retatrutide, and separate laboratory testing reported the same month found an unapproved retatrutide product at double its advertised concentration. The September case is the first TGA laboratory analysis confirming a product sold as retatrutide that contained none of the labelled compound.
The enforcement backdrop
The advisory is the latest step in a year-long regulatory build-up. On 10 June 2026 the TGA added unapproved peptide products to its formal compliance priority areas for 2026-27. The TGA notes that supplying or advertising unapproved therapeutic goods in Australia is prohibited unless an exemption applies, and that consequences for non-compliance may include infringement notices, direction or prevention notices, or civil and criminal penalties.
Prescriber guidance lands two days later
On 16 September the Australian Health Practitioner Regulation Agency (AHPRA) published new guidance for practitioners who prescribe off-label or unapproved medicines, including medicines intended for compounding, accompanied by published case studies. The guidance states that AHPRA “may investigate the practice of practitioners with high rates of prescribing or compounding of any scheduled medicine, even if we have not received a complaint”, and that “patient demand alone is not a valid reason to prescribe a medicine”.
One case study describes a doctor prescribing a range of unapproved peptides promoted for “anti-ageing” and “faster muscle repair”. Medical Board of Australia chair Dr Susan O’Dwyer said existing professional standards “apply to practitioners who are active in these new pharmaceutical frontiers”. AHPRA chief executive Justin Untersteiner said the regulator does not need to wait for a notification to act: unusual prescribing patterns or inappropriate advertising can trigger direct engagement with a practitioner or referral to other agencies.
What it means for the research market
The case illustrates the verification gap in unregulated supply chains. The product reached a consumer in an unmarked vial with no certificate of analysis and no traceable manufacturer, and the contents did not match the label at all. For buyers of research compounds, the documented failure modes now include both absence of the labelled compound and concentrations well above the stated level, which makes batch-level third-party verification the only practical check on declared contents.
What to watch
The TGA’s investigation is working to trace the source or supply of counterfeit retatrutide products and remove them from the market. Any resulting infringement notices or penalty outcomes would be the most concrete public results since the June compliance priority took effect. AHPRA has separately flagged forthcoming conflict-of-interest guidance and telehealth information for patients. Together, the two announcements show Australian regulators applying product-safety and prescriber-conduct levers in parallel as the unapproved peptide market continues to grow.
Sources
- Therapeutic Goods Administration, “TGA tests counterfeit retatrutide product following serious adverse event report,” safety advisory, 14 September 2026
- Rachel Carbonell, “Patient suffers torn oesophagus after using unapproved peptide, prompting fresh warnings,” ABC News, 14 September 2026
- Michelle Wisbey, “Patient suffers torn oesophagus after counterfeit peptide use,” newsGP (RACGP), 14 September 2026
- Michelle Wisbey, “AHPRA launches new guidance in peptide prescribing crackdown,” newsGP (RACGP), 16 September 2026
- Kate Cowling, “Fake peptide alert after patient suffers torn oesophagus,” Australian Journal of Pharmacy, 17 September 2026
- 7NEWS, “Fresh warning after patient suffers torn oesophagus from counterfeit drug sold as retatrutide,” 15 September 2026
For educational purposes only. This content is informational and reflects publicly reported developments. It is not legal, medical, or regulatory advice. Consult a qualified professional for compliance questions.